Main Article Content
Objective: Posaconazole is used to treat oral candidiasis in patients who are severely immunocompromised.
Posaconazole is categorized under BCS Class-Ⅱ drug, i.e., low solubility and high permeability. Posaconazole
has very poor water solubility. The current study aimed to improve water solubility of posaconazole using
different approaches. Materials and Methods: To enhance the solubility of drug, two methods, inclusion
complex and cosolvency approach, were performed. In inclusion complex method, beta-cyclodextrin (β-CD)
and hydroxypropyl β-CD (HP-β-CD) were used for the preparation of inclusion complex. In cosolvency method,
two different solvents polyethylene glycol-400 (PEG-400) and propylene glycol (PG) were used. Results: The
inclusion complex of HP-β-CD was prepared by physical mixing, kneading, and solvent evaporation methods
by taking 1:0.5, 1:1, and 1:2 molar ratio of Drug: HP-β-CD. From the results of dissolution study of complex, it
was observed that there was no significant improvement in solubility of drug. In cosolvency approach, maximum
solubility of drug was found in a ratio of 0:100% v/v for both solvents. The solubility of drug in Water: PEG- 400
and Water: PG solvents were found to be 20.228 ± 0.0169 mg/mL and 17.204 ± 0.0178 mg/mL, respectively.
Conclusion: In cosolvency method, it was observed that drug has more solubility in PEG- 400 compared to PG.
Hence, PEG-400 solvent was selected for drug solubilization.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.